ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2723

Role Of Interferon-Inducible RNA-Dependent Protein Kinase In The Pathogenesis Of Systemic Lupus Erythematosus

Aurélie De Groof1, Benoît Van den Eynde2, Frédéric A. Houssiau3 and Bernard Lauwerys1, 1Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 2Institut de Duve, Université catholique de Louvain, Brussels, Belgium, 3Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Pathophysiology and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: 2013 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

Session Type: Abstract Submissions (ACR)

Background/Purpose: PRKR (interferon-inducible RNA-dependent protein kinase) is an intracytoplasmic molecule that induces the production of interferon(IFN)-induced genes upon binding of double-stranded RNA viruses. PRKR is spontaneously over-expressed in PBMC from systemic lupus erythematosus (SLE) patients, and we previously demonstrated that in vitro exposure of SLE cells to 2-aminopurine (a pharmacological inhibitor of PRKR) results in a significant inhibition of IFN-induced genes and immunoglobulin production. In the present study, we wanted to further investigate the role of PRKR in the pathogenesis of SLE.

Methods: Intraperitoneal 2-aminopurine versus PBS injections were administered to (NZB x NZW)F1 mice three times a week for a period of 2 months. In addition, PRKR-KO mice were backcrossed in B6.Sle1.Sle2.Sle3 tricongenic SLE-prone mice, resulting in the generation of PRKR-KO versus WT tricongenic animals. Exploratory studies on the role of PRKR in dendritic cell differentiation were performed using bone marrow cells from the original PRKR-KO mice versus Balb/c controls. The roles of 2-aminopurine and 6-mercaptopurine on IFN-induced gene expression were evaluated in TLR3-transfected HEK293 cells.

Results: While dsDNA antibody (Ab) titers and proteinuria significantly increase over time in PBS-treated (NZB x NZW)F1 mice, this is not the case in 2-aminopurine treated animals. 2-aminopurine therapy also results in a significant improvement of glomerulonephritis activity scores upon histological examination of the kidneys. Our first observations in PRKR-KO versus –WT SLE-prone mice indicate that dsDNA Ab titers display a significant increase from month 2 to month 10 in PRKR-WT B6.Sle1.Sle2.Sle3 mice, and this is not observed in their PRKR-KO littermates.

IL-4 and GM-CSF exposure of bone-marrow cells results in the generation of myeloid-derived dendritic cells (moDC). We observed that the percentage of bone-marrow-derived CD11c-positive cells was significantly decreased in PRKR-KO mice, compared to Balb/c age- and gender-matched animals. Similarly, CD86-positive CD11c cells were significantly less numerous in PRKR-KO compared to Balb/c animals.

Using 2-aminopurine and PRKR siRNA, we demonstrated that PRKR is involved in TLR3 signal transduction in TLR3-transfected HEK293 cells. Thus, poly I:C-induced expression of IFNβ and IFN-induced genes is abrogated in these cells upon PRKR blockade. Intriguingly, we found that exposure of these cells to 6 mercaptopurine resulted in the same inhibitory effects on IFNβ and IFN-induced gene expressio.

Conclusion: Our data indicate that PRKR, an intracytoplasmic danger-recognition molecule that has the ability to stimulate the expression of IFN-induced genes, is involved in the pathogenesis of SLE. The role of PRKR in the pathogenesis of the disease might be mediated by an increased differentiation and maturation of moDC, a hypothesis that we will verify in our PRKR-KO versus –WT SLE prone animals. Preliminary data indicate that the activity of PRKR is modulated by 6-mercaptopurine, the active metabolite of azathioprine.


Disclosure:

A. De Groof,
None;

B. Van den Eynde,
None;

F. A. Houssiau,
None;

B. Lauwerys,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-interferon-inducible-rna-dependent-protein-kinase-in-the-pathogenesis-of-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology